321 – 330 of 422
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression.
(
- Contribution to journal › Article
-
Mark
Microarray-based Analyses of Hypoxia-induced Transcriptional Changes in Breast Cancer Cell Lines
(
- Contribution to journal › Article
-
Mark
Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers.
(
- Contribution to journal › Article
-
Mark
The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
(
- Contribution to journal › Article
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
(
- Contribution to journal › Article
-
Mark
High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells.
(
- Contribution to journal › Article
-
Mark
Differential expression of tissue factor (TF) in calcineurin inhibitor-induced nephrotoxicity and rejection-implications for development of a possible diagnostic marker.
(
- Contribution to journal › Article
-
Mark
A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer.
(
- Contribution to journal › Article
-
Mark
ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells.
(
- Contribution to journal › Article